主管单位:中华人民共和国
国家卫生健康委员会
主办单位:
总编辑:杨秋
编辑部主任:吴翔宇
邮发代号:80-528
定价:28.00元
全年:336.00元
Email:zgyy8888@163.com
电话(传真):010-64428528;
010-64456116(总编室)
作者:高铭鑫1王亚培2于洋1
英文作者:Gao Mingxin1 Wang Yapei2 Yu Yang1
单位:1首都医科大学附属北京安贞医院心脏外科100029;2中国人民大学化学系,北京100872
英文单位:1Department of Cardiac Surgery Beijing Anzhen Hospital Capital Medical University Beijing 100029 China; 2Department of Chemistry Renmin University of China Beijing 100872 China
英文关键词:Coronaryarterybypassgrafting;Restenosisofveingraft;Targeteddrugcarriermaterial
移植静脉再狭窄严重影响冠状动脉旁路移植术患者预后。临床术后常规药物对缓解移植静脉的内膜增生疗效甚微,且血管外支架及内膜载药材料均存在力学及生物性质的不可控,是目前移植静脉再狭窄研究的瓶颈。随着材料学发展,具备组织相容性好、细胞毒性小、理化性质可控的载药材料逐渐可以满足移植静脉再狭窄防治的需求,通过医学与材料化学的跨领域交叉与协作,寻找合适的载药材料,对提高冠状动脉旁路移植术后移植静脉远期通畅率具有极其重要的意义。本文对近年来基于材料学改善冠状动脉旁路移植术后移植静脉再狭窄的相关治疗进展作简要综述。
Restenosis of vein graft seriously affects the prognosis of coronary artery bypass grafting. Conventional medicationis insufficient in reducing intimal hyperplasia of vein graftafter surgery. Mechanical and biological properties of external stent and drug carrier materials are uncontrollable. With the development of material science, drug carrier materials with good histocompatibility, low cytotoxicity, controllable physical and chemical properties can be used in prevention and treatment of vein graft restenosis. It is of great significance to find suitable drug carrier materials through cross-disciplinary interaction and collaboration between medicine and material chemistry, so as to improve the long-term patency rate of vein graft after coronary artery bypass grafting. This paper reviewed the progress in treatment of vein graft restenosis after coronary artery bypass grafting based on material science.
copyright
地址:北京市朝阳区安贞路2号首都医科大学附属北京安贞医院北楼二层
电话:010-64456116 传真:010-64428528 邮编:100029 Email: zgyy8888@163.com
网址: 京ICP备2020043099号-3
当您在使用本网站投稿遇到困难时,请直接将稿件投送到编辑部邮箱zgyy8888@163.com。